Heidi Anne Duerr, MPH

Timothy Wilens, MD, shares highlights and clinical implications for ADHD from the APSARD Annual Conference.

Barry Herman, MD, shares insights on real-world data of online ADHD assessment tool and telepsychiatry.

Allison Baker, MD, shared insights on supporting women before, during, and after pregnancy at the APSARD conference.

Benjamin E. Yerys, PhD, shares clinical insights on the impact of the comorbidity at the APSARD Conference.

Poster presented at the APSARD Annual Conference demonstrates the importance of genetic testing in ADHD.

Explore the complex relationship between gender, sexual health, and mental health with insights from expert Eugene T. Lucas Jr, DNP, CRNP, FNP-BC, APMHNP-BC.

Acceptance paves the way for a critical trial of COMP360, a synthetic psilocybin that has the potential to transform PTSD care.

Reviva Pharmaceuticals announced FDA recommendations from their pre-NDA meeting on brilaroxazine for schizophrenia.

Discover new research on schizophrenia treatments, including digital therapeutics and valbenazine, showcasing significant improvements in patient outcomes.

Gerald A. Maguire, MD, explores the importance of understanding stuttering in psychiatry, emphasizing the need for research, collaborative care, and awareness.

Data presented at the ECNP Conference showed CT-155 has promise in reducing negative symptoms of schizophrenia.

Half of patients with stuttering also experience anxiety, highlighting the psychiatrist’s role in care and support.

Because stuttering represents a spectrum disorder, a spectrum of treatments are needed.

Shelly Jo Kraft, MS, PhD, lays the foundation for a new approach that emphasizes the role of comorbidities in stuttering.

Shahriar SheikhBahaei, PhD, discusses how animal models may lead to better treatments.

Collaborating with speech pathologists and others improve care for patients who stutter.

Shahriar SheikhBahaei, PhD, shares insights into the neurobiology of stuttering at STARS conference.

Gerald A. Maguire, MD, details the unmet needs in stuttering at the inaugural conference.

More than 20 years later, what have we learned about PTSD, resiliency, and trauma?

Gerald Maguire, MD, shares insights on agitation in Alzheimer disease at the Southern California Psychiatry Conference.

Maguire discussed the differential diagnosis of bipolar depression at the Southern California Psychiatry Conference.

Yvette Elpidio, PMHNP-BC, shares insights on NMDA agonists at the Southern California Psychiatry conference.

Deb York, PMHNP-BC, sheds light on postpartum psychiatry at the conference.

Discover promising new treatments for schizophrenia, including NBI-1117568 and CPL’36, showcasing significant symptom improvements and safety profiles.

Transcend Therapeutic announces breakthrough therapy designation for TSND-201 for treating PTSD.

Rebecca Barbee, PA-C, shares tips on addressing the heat wave and its implications when talking with patients.

NRx Pharmaceuticals advances NRX-100, a preservative-free ketamine, through a fast-tracked FDA review for treating suicidal depression and PTSD.

The RECOVER open label trial demonstrated positive results for brilaroxazine for schizophrenia.

Dr Goldberg and Dr Anita share previews of the upcoming ASCP Annual Meeting in Scottsdale, Arizona.

Although there are topics in psychiatry that not exciting, Dr Ghaemi sees plenty of opportunities.